Anti-myeloma effects of ruxolitinib combined with bortezomib and lenalidomide: A rationale for JAK/STAT pathway inhibition in myeloma patients-Reference-Cited by-同舟云学术

Anti-myeloma effects of ruxolitinib combined with bortezomib and lenalidomide: A rationale for JAK/STAT pathway inhibition in myeloma patients

Published:2017-09 Issue: Volume:403 Page:206-215
ISSN:0304-3835
Container-title:Cancer Letters
language:en
Short-container-title:Cancer Letters

Author:

de Oliveira Mariana B.,Fook-Alves Veruska L.,Eugenio Angela I.P.,Fernando Rodrigo C.,Sanson Luiz Felipe G.,de Carvalho Mariana F.,Braga Walter M.T.,Davies Faith E.,Colleoni Gisele W.B.

Funder

Conselho Nacional de Desenvolvimento Científico e Tecnológico (CNPq), Brazil

FAPESP

Publisher

Elsevier BV

Subject

Cancer Research,Oncology

Reference29 articles.

1. Advances in the autologous and allogeneic transplantation strategies for multiple myeloma;Nishihori;Cancer Control,2011

2. Risk of progression and survival in multiple myeloma relapsing after therapy with IMiDs and bortezomib: a multicenter international myeloma working group study;Kumar;Leukemia,2012

3. Stat3 as an oncogene;Bromberg;Cell,1999

4. STAT3 is essential for Hodgkin lymphoma cell proliferation and is a target of tyrphostin AG17 which confers sensitization for apoptosis;Holtick;Leukemia,2005

5. Constitutively activated STAT3 promotes cell proliferation and survival in the activated B-cell subtype of diffuse large B-cell lymphomas;Ding;Blood,2008

Cited by 33 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. A Phase I Trial Evaluating the Addition of Lenalidomide to Patients with Relapsed/Refractory Multiple Myeloma Progressing on Ruxolitinib and Methylprednisolone;Targeted Oncology;2024-04-20

2. The ERK1/2-Elk1, JNK-cJun, and JAK-STAT Transcriptional Axes as Potential Bortezomib Resistance Mediators in Prostate Cancer;2024-04-20

3. Ruxolitinib induces apoptosis and pyroptosis of anaplastic thyroid cancer via the transcriptional inhibition of DRP1-mediated mitochondrial fission;Cell Death & Disease;2024-02-09

4. Effects of Ruxolitinib on Myeloproliferative Neoplasms via the Negative Regulators;Clinical Laboratory;2023

5. ERBB1/EGFR and JAK3 Tyrosine Kinases as Potential Therapeutic Targets in High-Risk Multiple Myeloma;Onco;2022-10-14